Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Immunai

Request full access

Mapping and reprogramming the immune system with single-cell biology and AI to power new therapeutic discoveries, accelerate drug development, and improve patient outcomes

New York City, United StatesFounded 2019Biotech & Life Sciences

Immunai in the New York City ecosystem

Live from Dealroom

The Immunai office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

15 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed2 investors entered at this stage

Series A4 investors entered at this stage

  • Dexcel Pharma
  • Schusterman Foundation
  • Catalio Capital Management
  • Duquesne Family Office

Series B and later9 investors entered at this stage

  • Stanford University
  • Koch Disruptive Technologies
  • Icon Ventures
  • Parker Institute for Cancer Immunotherapy
  • Alexandria Venture Investments
  • Talos
  • 8VC
  • Piedmont Healthcare
  • Massachusetts Institute of Technology
Employees mapped 176 incl. 20 AI specialists
Founders Hidden — book a demo/100 quality score
Key operators 16 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia 4 alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Patents

Estimated portfolio value
$90k

3 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

See Immunai on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.